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Abstract Oxidative damage triggers extensive repair in gam-
etes and thereafter in the zygote but it results in clinically
relevant damage when affecting the maturation of the gametes
chromatin, i.e. padlocking and epigenetic marking. It associ-
ates with defective DNAmethylation and/or with oxidation of
the methyl marks leading to derangement of gamete epige-
netics, defects of chromatin condensation and aneuploidy. A
proper feed to the one carbon cycle has the potential to stim-
ulate the endogenous antioxidant defences, i.e. gluthatione
synthesis, and to activate compensative homeostatic mecha-
nisms restoring both the oxy-redox balance and DNA meth-
ylation, which are indeed strictly cross-regulated. This has
been shown to produce measurable clinical improvements of
male reproductive potential in pilot studies herein
summarised. However, the effects of dietary habits and of
supplementations are variable according to the individual ge-
netic substrate, as genetic variants of several of the concerned
enzymes occur with high frequency. Individual risk assess-
ments and personalised interventions are still difficult to im-
plement, in the meantime, a very varied diet may facilitate
metabolic compensation in the majority of the cases. This
review aims to report on the mechanisms of damage, on the
opportunities to modulate the physiologic oxy-redox
homeostasis by means of a varied diet or dietary supplements
and on the open issues related to the genetic variability of the
population.
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Introduction
The energy supply to life on the Earth planet is mostly based
on oxygen metabolism, and any healthy cell is well equipped
to manage the possible damage from oxidising agents.
Damage will occur only when the load of oxidative species
exceeds the capacity of the cellular antioxidant mechanisms,
which are largely dependent on the assumption of dietary
substrates and micronutrients [1] and on the individual genetic
substrate [2].
Among the cellular species, gametes are the most sensitive
to these imbalances due to their long maturation process in
contact with the environment, which is particularly true for the
male gametes. Evolution selected this type of process likely
because gametes have the specific task to collect environment
signals and to pass them to the offspring in the form of epige-
netic marks [3]. This leads to two simple concepts: First, only
a well-balanced metabolism will support proper gamete mat-
uration and their reproductive competence; Secondly, as gam-
ete deterioration is sensitive to environmental signals, similar-
ly their improvements should be sensitive to feeding signals, if
we know which the good ones are.
Therefore, it is worth putting more effort into the compre-
hension of oxy-redox homeostasis, the consequences of
supporting interventions and the complex interaction with
the environment, including feeding habits and genetic variants
in the population.
Capsule A varied and balanced diet and/or physiology-oriented supple-
mentations may revert oxidative damages to gametes, whether or not
linked to genetic traits, for improved reproductive outcomes.
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Oxidative damage affects gamete chromatin
and epigenetics
Oxidative molecular damage occurs in all cells but it is very
likely to be repaired. Also spermatids, oocytes and thereafter
zygotes possess powerful, although finite, DNA repair capac-
ity [4]. On the other side, compensative or repairing mecha-
nisms capable of correcting damage beyond simple molecular
oxidations, i.e. to the chromatin structure, have not yet been
described. It is now evident that, besides the genes, the chro-
mosomes of gametes provide a structural framework that is
required for proper embryonic development [5]. Oxidative
aggression may affect the chromatin structure and the epige-
netic regulation of gametes in at least two relevant manners: in
sperm, by affecting the protamin content [6]; In both sperm
cells and oocytes by misleading the epigenetic marks, i.e. by
affecting DNA methylation patterns.
The methylation of DNA occurs at cytosine residues, parts
of Bcytosine-phosphate binding-guanosine^ repeats called
CpGs. The promoters of many genes contain areas enriched
of CpG repeats called CpG islands. The extensive methylation
of the CpG islands causes loss of affinity of the gene pro-
moters for the transcription factors and results in gene silenc-
ing [7]. In addition, the methylation of CpGs, together with
histone lysine methylation [8], also regulates chromatin state
so that extensive methylation is followed by chromatin com-
paction to generate a transcriptionally silent state that is an
essential maturation phase of both sperm [9] and oocytes [10].
The CpGs and the CpG islands are the main target of oxi-
dative damage. The oxidation of the methylated cytosines
within CpGs produces Hydroxy-methyl-Cytosine (OH-mC),
which is the starting step for active demethylation [11] and
may result in loss of epigenetic marks. In addition, the oxida-
tion of either methyl-cytosine or guanosine (to form 8-Oxo-
Guanosine) within otherwise properly methylated CpG
islands causes loss of the inhibition of the binding of transcrip-
tion factors, i.e. loss of the epigenetic regulation (Fig. 1). This
has been proposed as a main mechanism for the loss of epi-
genetic regulation following environmental damage in neo-
plastic [12] and neurodegenerative diseases [13] and is likely
to be the most clinically relevant consequence of excessive
oxidative exposure: The loss of epigenetic regulation in gam-
etes leads to the risk of an erratic phenotype, which will cer-
tainly affect the fertilization potential as well as the activation,
viability and the development of the generated embryos.
Oxidative stress-induced perturbations of DNA methyla-
tion also affects chromosome stability and segregation and
may lead to aneuploidy of both sperm and oocytes. Meiosis
requires full chromatin condensation to facilitate the process
[14], which is called heterochromatin state. Only the areas
intended for homologous chromosome recombination, the re-
combination hotspots, remain hypomethylated and
decondensed to allow the recombination process [15]. Thus,
hypomethylation of CpG islands attracts the recombination
machinery, which has been well shown in germline dog
models [16]. In mice oocytes, the abnormal axial chromatid
condensation during meiosis alters chromosome segregation
by interfering with both chromosome-microtubule interac-
tions and sister chromatid separation [17]. Similar mecha-
nisms seem to be in place in spermatogenesis and to have an
impact on male fertility [18]. The oxidation of chromosome
telomeres also contributes to gamete aneuploidy. Telomeres
consist of guanosine enriched, repeated TTAGGG sequences
that are several thousand base pairs long. Telomere GGG re-
peats where shown to be a preferential target of oxidative
damage in human primary fibroblasts: while genomic damage
gets extensively repaired, telomere GGG oxidation persists
and leads to telomere shortening and chromosomal instability
[19]. Differently from fibroblasts, gametes express telomerase
activity and may repair the damage; nevertheless, human oo-
cytes with telomere DNA deficiency are prone to aneuploidy
development during meiosis [20]. Furthermore, oxidative
damage causes overriding of the spindle check point, the safe-
guard mechanism that halts anaphase onset until meiotic spin-
dle assembly, which provides a further link between oocyte
aneuploidy and oxidative stress [21].
In summary, oxidative damage is likely to be of clinical
relevance when and if resulting in derangement of epigenetic
regulation as well as in perturbation of the gamete chromatin
condensation phase, which does not leverage on repair mech-
anisms. The supportive interventions should be aimed at re-
storing both the full efficiency of the 1 carbon cycle (1CC)
pathway, ensuring timed availability of activated methyl
groups for DNA methylation, and proper reactivity by the
intracellular antioxidant system, that will protect the epigenet-
ic marks from misleading oxidation. Noteworthy, from a met-
abolic point of view, the 1CC and the antioxidant defences are
a unique functional unit, i.e. two sides of the same coin [22].
Physiologic oxy-redox homeostasis
In physiologic conditions, in both somatic and germline cells,
any excess of reactive oxygen species (ROS) activates remov-
al bymeans of a variety of biochemical reactions and enzymes
forming an anti-oxidant cascade that leverages on a wide list
of mediators. These include enzymatic (superoxide dismut-
ase—SOD, glutathione peroxidase—GPx, catalase—CAT)
and non-enzymatic (ascorbic acid—vitamin C, tocopherol—
vitamin E, carotenoids, flavonoids and others) antioxidants
[23]. On top of this cascade, there is a kind of redox buffering
system based on a thiol antioxidant, the tripeptide glutathione
(GSH) [24]. Besides acting as a cofactor for GPx, GSH can
directly scavenge hydroxyl radicals and singlet oxygen. More
importantly, GSH is able to regenerate the most important
cellular antioxidants including vitamins C and E.
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GSH is abundant in the cytosol, the mitochondria and
the nuclei of all cells [25]. It is able to release a reducing
equivalent (E°) to any acceptor generating glutathione
disulphide (GSSG) and can be regenerated from NADH
and NDAPH. More commonly, GSH is available by de
novo biosynthesis mainly by means of the so-called
transsulfuration pathway, which is ubiquitous and mas-
sively cycling in all cells [26]. The starting substrate
for GSH de novo biosynthesis is another sulphur but
nonproteogenic aminoacid, homocysteine (Hcy), that re-
acts with serine to form cystathionine and thereafter
binds glutamate and glycine to form the active tripeptide
(Fig. 2, lower panel). The pathway for GSH synthesis is
of paramount importance because GSH must be available
on site to neutralise ROS just in time. There are no
dietary sources or storage; The oxy-redox homeostasis
is based on GSH availability by regeneration and de-
novo synthesis where, when and how long it is needed
within a delicate and perfect homeostatic equilibrium.
The starting substrate for GSH de novo biosynthesis is Hcy,
which is in turn the end-product of the 1CC (Fig. 2, upper
panel): This pathway is the base of life on the Earth planet,
i.e. it is a main pathway for non-photosynthetic organisms to
add the carbon unit to molecules and its massive cycling is
essential for cell growth and differentiation. Briefly, the meth-
yl group of methionine, after an activating adenylation to form
S-adenosyl-methionine (SAMe), is released to any acceptor
and generates Hcy. Hcy can thereafter be re-methylated to
methionine with a methyl group donated by either methyl-
tetrahydro-folate or betaine (trimethyl-glycine). Lack of Hcy
recycling and its accumulation is highly toxic to cells, since it
is a powerful pro-oxidant and a strong inhibitor of
transmethylation [27].
Whether or not Hcy is focussed on GSH synthesis de-
pends on the activity of a key enzyme, cystathionine beta
synthase (CBS), a tetrameric enzyme having pyridoxine
(vit. B6) as the essential co-factor and binding Hcy by
means of zinc fingers [28]. It is highly active in the liver,
pancreas and cerebral cortex; however, the gene expres-
sion has been also shown in murine testicular tissue [29]
and granulosa cells where gene silencing causes follicular
arrest [30]. CBS responds to a very peculiar mechanism of
activation that renders this enzyme the epicentre of cellu-
lar metabolism. Briefly, the enzyme is made of 4 CBS
protein domains complexed around a heme group similar
to the one occurring in haemoglobin. The iron of the heme
group acts as a redox sensor: In the inactive state it occurs
as ferrous iron (Fe++) whereas anytime the cell environ-
ment becomes oxidative it turns in the ferric state (Fe+++
). As the iron oxidises CBS enters in its active conforma-
tion configuring a typical redox regulation that opens or
closes the transulfuration pathway as a reversible switch
[24, 31]. However, in order to acquire high cyclicity and
to generate high rate GSH output, mammalian CBS re-
quires a second activation: a moiety of SAMe, i.e. the
activated methyl group for transmethylation generated
within the 1CC, must bind each CBS domain exerting
an allosteric up-regulation that increases the enzyme ac-
tivity approximately fivefold [28, 32] (Fig. 3).
The regulation of CBS activity, besides being the core
of cell resistance to oxidative loads, is a paradigmatic
example of how cell homeostasis works. The 1CC, being
the pathway for adding the carbon units to molecules,
ensures growth and differentiation of the cells and has a
kind of metabolic priority. Within the pathways fed by the
1CC, DNA methylation has a further priority. The ability
Fig. 1 Epigenetic instability from oxidative damage. a The methylation
of cytosine (filled circles) within CpG repeats to form methyl cytosine
causes loss of affinity of the transcription factors for the promoter and
silencing of the gene. b If the cytosines are not methylated (empty circles)
due to lack of SAMe or if the methylation mark is lost due to de-
methylation triggered by methyl cytosine oxidation, the gene is not
anymore silenced and may undergo inappropriate expression. c If either
the methyl cytosine or the guanosine of the CpG repeat are oxidised
(small filled circles), the domain reverts from hydrophobic back to
hydrophilic and the transcription factors recover the ability to bind and
to express the gene in spite of the methylation of the CpG island. Both
cases b and c lead to epigenetic instability
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to defend the cell against oxidations is thereafter relevant
only for cells that are duly growing with a positive bal-
ance of activated methyl groups (SAMe) to switch on
GSH synthesis, otherwise the cell will be addressed to
abortive apoptosis. The final effect is that the antioxidant
defences will be active and efficient only in cells that are
metabolically healthy.
Issues with oral antioxidants
There is good consensus that oxidative damage to male gam-
etes represents a relevant clinical issue [33], which opens the
idea that supplementation with oral antioxidants might im-
prove gamete quality and the chance to achieve a pregnancy.
Accordingly, several papers aimed to test this hypothesis
Fig. 3 Regulation of cystathionine-beta-synthase (CBS) activity. The
enzyme is formed by a tetramer of CBS domains complexed with a
heme functioning as a redox sensor. The oxidation of the heme group
activates the enzyme. However, a significant activity funneling
homocysteine into the trannssulfuration pathway will only occur if
SAMe is available and binding to the carboxy-terminal end of the CBS
domains. Thus, full efficiency of the transsulfuration pathways for GSH
synthesis will only occur after the requirement for activated methyl
groups (SAMe) for the one carbon cycle is satisfied
Fig. 2 Connection between the one carbon cycle and the transsulfuration
pathway (GSH synthesis). Upper panel The methyl group of methionine
is activated by adenylation to form S-Adenosyl-Methionine (SAMe) that
acts as the universal methyl donor for any acceptor including DNA: a
molecule of homocysteine is formed. Homocysteine can be either re-
methylated from folates or betaine or enter the transsulfuration pathway
for the synthesis of glutathione (GSH). Lower panel Homocysteine is
complexed with serine to form cystathionine and to feed the de-novo
synthesis of GSH
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published during the last 15 years consistently showed some
positive effects of oral antioxidants onmale gametes, either on
sperm motility or on sperm morphology. Nevertheless, the
latest Cochrane review on the antioxidant treatment of male
infertility [34] concluded for low quality evidence that antiox-
idant supplementation in subfertile males may improve live
birth rates and clinical pregnancy rates for couples attending
fertility clinics. The same considerations apply to female in-
fertility where clinical data in support are even weaker [35].
This could be probably ascribed to heterogeneity/weakness in
studies design. In addition, speaking of male treatments, the
ability of the oocyte of concern to repair damages to sperm
DNA [4] may act as a confounding factor when assessing the
treatment effect on the male side. However, metabolic issues
may also apply.
The small effect on pregnancy rates is in part explained by
the aggressiveness of oral antioxidants, forcing the cellular
environment to the redox state, in front of the delicate metab-
olism of gametes that necessitate a perfect oxy-redox balance.
Strong antioxidant cocktails may cause an excessive removal
of oxygen free radicals essential for the regulation of several
sperm functions: this may negatively affect capacitation and
the acrosome reaction [36] and may induce a Breductive
stress^ as a rebound effect [37]. This was clinically confirmed
by the worsening of the sperm nuclear condensation and
padlocking of the protamines, a very negative outcome, that
proportionally mirrored the improvements of the DNA frag-
mentation when strong antioxidants (Vit. C + Vit E + beta-car-
otene + zinc + selenium) were administered to infertile men
[38].
It is anticipated that the reductive stress will interfere with
the process of protamination and DNA synthesis. Both pro-
cesses imply the resolution of the so-called supercoiling of
DNA, which happens by extensive cut and paste work by
the enzymes topoisomerase 2B (TOP2B) and poly-ADP-
ribose-polymerase (PARP) [39]. TOP2B generates
doublestrand breaks to allow distension of the double helix.
Thereafter PARP adds to the break a chain of poly-ADP-
ribose (PAR) that causes detachment of TOP2B and allows
the process of recatenation. PARP consumes huge amounts of
oxidised NAD (NAD+) as the ribose source for the synthesis
of PAR: as DNA replication starts there is a sharp fall in cell
NAD+ content and activation of ATP hydrolysis to feed
NAD+ availability [40]. Any reductive stress will cause im-
balance of NAD toward its reduced form (NADH) [41]
resulting in shortage of NAD+, in metabolic inhibition of
PARP and in accumulation of unrepaired double strand breaks
for imbalanced TOP2B activity.
Another problem is that, whatever the composition of an-
tioxidant cocktails, it will have to contain a finite number of
substances. Each of these substances will influence a finite
number of oxy-redox reactions that, according to the dose of
antioxidants administered, will be possibly imbalanced
toward the reductive stress. Meantime, all the other oxy-
redox reactions will remain unaffected. The final outcome is
failure in equilibrating the intracellular environment and a
possible reductive stress in selected pathways. This approach
may be clinically advantageous any time the objective is the
correction of a specific, well-known pathway but it is not
suitable if the aim is to achieve a perfect oxy-redox balance
and efficient DNA replication and protamination as required
by gametogenesis.
In summary, as the harmful effect of oxidative stress on
gametes health is unquestionable and assumed the need to
counteract the oxidative aggression in the sake of improved
gametes quality, alternatives to the straight oral antioxidants
administration are worthy to be explored.
How to feed and stimulate the antioxidant system
Once understood, the role of the 1CC in the activation of the
physiologic antioxidant responses, it can be postulated that a
robust support to the 1CC could result in improved DNA
methylation, sustaining gametes maturation, and activation
of the endogenous antioxidant system, configuring a physio-
logic and self-regulated antioxidant activity devoid of any risk
of Breductive stress^. The 1CC is strictly dependant on dietary
sources of methyl donors and of other essential substances,
absolute or relative shortages may occur. In addition, a heavier
endogenous (e.g. inflammation) or exogenous (e.g. pollutants)
load of oxidative aggression may be responsible for a relative
shortage also in individuals otherwise following a relatively
healthy lifestyle.
The list of dietary substances useful to sustain the 1CC is
quite short and simple. Folates are to be included as the source
for methyl groups for Hcy re-methylation. Quantities of ribo-
flavin (vit. B2) and niacin (vit. B3) will support the conversion
of folic acid to its active reduced form by the enzymeMethyl-
Tetra-Hydro-Folate-Reductase (MTHFR). Vitamin B12 is
then necessary to pass the methyl group from folates to Hcy.
Finally, zinc, that has no body reservoirs and is strictly depen-
dant on daily feeding [42], is also necessary because the main
enzymes involved (MTHFR,MTRR, CBS) work by means of
zinc fingers. It is to be noted that only chelated zinc is actually
bio available and that most of the commercial supplements
contain zinc oxide that provides a negligible support [43].
The above substances in due amounts have the potential to
saturate the 1CC and to generate an excess of activated methyl
groups (SAMe) for the activation of CBS and for an efficient
GSH output anytime it is needed. GSH synthesis can be fur-
ther supported providing its necessary co-factor pyridoxine
(vit. B6) and, again zinc. In addition, a cysteine donor (e.g.
N-acetyl-cysteine or L-cystine) has the potential to feed GSH
synthesis downstream to CBS and to allow the enlargement of
the GSH-GSSG pool if it is needed.
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Clinical results
A nutritional supplement containing all the substances neces-
sary to support the 1CC (vit. B2, B3, B9, B12 and chelated
zinc) and the GSH production (cysteine donor, vit. B6 and
zinc) was formulated and addressed to clinical trials. The sup-
plement also contained small amounts of Vit. E (12 mg) as a
stabilizer (to prevent premature oxidation of the cysteine do-
nor) and betalain and quercetin of vegetal origin to protect
membrane lipids (CondensylTM). Indeed betalaines have the
property to stratify on plasma membranes where they act as
suicide oxidation substrates to prevent the trigger of the
lipoperoxidative cascade so to further aid sperm motility.
This nutritional intervention was tested in male [44–46] and
female [46] partners in couples with previous IVF/ICSI fail-
ures willing to undergo another ART attempt. These studies
included couples with at least 2 previous ART failures and
with a male partner showing sperm DNA Fragmentation
Index (DFI—Measure of oxidative molecular damage, as
a s s e s s ed by TUNEL) and /o r a Spe rm nuc l e a r
Decondensation Index (SDI—Measure of integrity of chro-
matin tertiary structure, as assessed by aniline blue stain-
ing) > 20 % irrespective of the other sperm parameters. A 4-
month nutritional support was prescribed.
The very first study was intended to confirm that: (i) The
above formula does indeed exert antioxidant modulation in
clinically significant amounts, and; (ii) The antioxidant gain
does not generate any reductive stress as previously seen with
oral antioxidants [38]. A total of 84 patients fulfilled the entry
criteria of this non comparative study [44], in 28 cases (33 %)
there was an associated female factor. For the first time ever,
both sperm indexes significantly improved (DFI from 29.7 to
23.1 %, p < 0.001; SDI from 40.1 to 36.3 %, p < 0.001)
confirming that the new support strategy is effective in
counteracting oxidative damage without negatively influenc-
ing (reductive stress) the nuclear decondensation. The study
also recorded the pregnancy outcomes and, given the inclu-
sion criteria, the results were encouraging. Eighteen couples
(21 %) experienced a spontaneous pregnancy during the treat-
ment, all of them ending with a live birth. The remaining 66
couples underwent a new ART attempt further resulting in 22
clinical pregnancies and in 15 live births. The overall clinical
pregnancy rate (CPR) and live birth rate (LBR) were 47.6 and
39.3 %, respectively.
The pregnancies seemed to be strongly related to the im-
provement of the sperm decondensation index (Table 1) but
the small sample size did not allow the calculation of a SDI
cut-off value predictive of a successful pregnancy. The higher
predictive value of the SDI compared to the DFI was expect-
ed. A well-compacted chromatin will protect the chromo-
somes from the oxidative burst of the acrosome reaction at
time of fertilization [47]; thus, it has a direct link with the
ability to fecundate by natural routes, which accounts for the
spontaneous pregnancies, and with the ability of the sperm to
activate the embryo. On the other side, the oxidative damage
to the genes, as reported by extensive DNA fragmentation,
will have a strong impact at time of expressing such genes,
i.e. on embryo viability, leading in case to pregnancy loss that
could not be detected with the study model of concern.
The intervention was then tested in comparison with a non-
treatment group using the same supplement [45] or a similar
one including also small amounts of natural direct antioxi-
dants (ProcreliaTM) [46]. The second comparative study [45]
included a female treatment arm: supplements were given to
couples with previous ART failures due to known female
factor. It is to be noted that in both the comparative studies
the controls were patients not willing to take antioxidants, thus
the studies were not truly randomized. In male treatments [45,
46], again, both the DFI and the SDI significantly decreased
whereas they did not change in their controls. It is noteworthy
that, differently from sperm parameters that show intra-
individual variability, these indexes of sperm damage are rath-
er stable over time without interventions. The pregnancy rates
were significantly higher in the treatment groups in all study
arms compared to untreated arms with a high rate of pregnan-
cies occurring spontaneously. Surprisingly, the pregnancy
gain from the female treatment [46] was at least as high as
the one recorded with male treatments, suggesting that the
impact of oxidative damage on female infertility may be sim-
ilar if not even larger. The pregnancy outcomes of the male
partners and their controls [44, 45] and of the female partners
and their controls [46] are summarized in Table 2.
Taken together, these data strongly support the idea that a
tailored nutritional intervention in support of the 1CC and of
GSH synthesis may have a fundamental impact on the repro-
ductive prognosis of couples resistant to ART cycles and, in
general, in infertile couples. The high rate of spontaneous
pregnancies, not recorded in control groups, may in part result
from a selection bias: repeated ART failures may have select-
ed couples with a mainmetabolic problem. As a matter of fact,
it has been demonstrated that morphologically normal sper-
matozoa with non-condensed chromatin may be found also in
subjects with normal sperm parameters [48]. Therefore, some
cases of idiopathic male infertility leading to unexpected ART
failures may be due to high, but yet undemonstrated, SDI
values due to metabolic reasons. Accordingly, adequate nutri-
tional care offered since the first referral to both partners of
couples with unexplained infertility might decrease the need
for repeated ART cycles and may also help to increase the
chances of IUI.
The strong relationship between the occurrence of a preg-
nancy and the improvement of sperm nuclear condensation in
the male partner (Table 1) may represent further proof of the
key role of chromatin structure in gametes’ reproductive com-
petence. The positive outcomes obtained in women may
suggest that a similar effect is also exerted on female
1638 J Assist Reprod Genet (2016) 33:1633–1648
gametes, although the lack of clinically suitable DNA damage
tests does not allow final confirmation.
Based on the negative effects of direct antioxidants on
sperm nuclear condensation [38], their indiscriminate use
should be avoided. These treatments should be prescribed
only to patients with confirmed damage under strict medical
control. On the other side, nutritional support based on the
modulation of the physiologic antioxidant system, e.g.
Condensyl, did not exert any counter effect and, on the con-
trary, improved the sperm nuclear decondensation while sig-
nificantly reducing DNA fragmentation. These treatments
could hence be offered to a larger population before seeking
pregnancy and without fixed limits of duration.
Does MTHFR genotype affect the outcome?
Once the clinical opportunities arising from a tailored supple-
mentation to the 1CC are understood, the next question is
whether such supplementation would benefit the carriers of a
deficient variant of the enzyme Methyl-Tetra-Hydro-Folate-
Reductase (MTHFR). The enzyme variants are thermolabile,
have a more rapid turn-over and exert reduced activity. The
deficit of the MHTFR function according to the genotype is
reported in Table 3 [49].
Genetic variants of the MTHFR gene indeed have a high
prevalence. The widely investigated C766T mutation has a
variable prevalence according to ethnicity and geographical
areas following a clear-cut north to south gradient with an
incidence of the TT homozygotes in newborns ranging from
<5 % in Northern Europe and Canada to >20 % in Southern
Europe andMexico [50]. However, also the A1298Cmutation
is common and sometime associated to the C766T mutation.
According to a well-designed study [51], analysing the geno-
type of a cohort of consecutive newborns in Southern Italy, the
C766T mutation was present in 79 out of 104 and in 23 of
them it was homozygous. In addition, 55 out of 104 carried the
A1298C mutation which was homozygous in 13 of them. A
combined C766Tand A1298Cmutation was found in 28% of
the tested newborns whereas triple mutations were rare and a
double homozygous state was not found, it is likely non-vital.
Recent metanalysis studies concluded for the MTHFR
C677T [52, 53] and A1298C [54] mutations to be a risk factor
for male infertility. The MTHFR genetic variants are also as-
sociated to female unexplained infertility [55] and have been
Table 1 DFI and SDI response to Condensyl according to clinical pregnancies, mean values, Mann-Whitney test [44]
Groups n (%) DFI SDI
Pre Post Δ % p Pre Post Δ % p
Any pregnancy
YES 40 (47.6) 29.4 % 20.1 % −9.3 % 0.168 40.6 % 29.3 % −11.3 % 0.000
NO 44 (52.4) 30.1 % 25.9 % −4.2 % 39.6 % 42.6 % 3.0 %
Spontaneous pregnancy
YES 18 (21.5) 23.2 % 18.4 % −4.8 % 0.571 44.8 % 29.8 % −15.0 % 0.000
NO 66 (78.5) 31.5 % 24.4 % −7.2 % 38.8 % 38.0 % −0.7 %
ART pregnancy
YES 22 (33) 34.4 % 21.4 % −13.0 % 0.046 37.2 % 29.0 % −8.2 % 0.001
NO 44 (67) 30.1 % 25.9 % −4.2 % 39.6 % 42.6 % 3.0 %
Table 2 Comparative studies
[45, 46]: pregnancies and
deliveries, mean values, Chi
square test
N of pts Pregnancies, n (%) Deliveries p
All Spontaneous
Only men treated, female partner Bnormal^ [45]
Treated 69 35 (50.7 %) 10 (29 %) 29 (42 %) 0.003
Controls 83 23 (27.4 %) 0 (0 %) 18 (21 %)
Only men treated, female partner Bnormal^ [46]
Treated 95 49 (56 %) 8 (16 %) 45 (47 %) 0.001
Controls 84 23 (27 %) 0 (0 %) 18 (21 %)
Only women treated, male partner Bnormal^ [46]
Treated 100 45 (45 %) 30 (67 %) 40 (40 %) 0.0001
Controls 73 10 (14 %) 0 (0 %) 8 (10.9 %)
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reported to cause a reduced number of retrieved oocytes in
women undergoing ART, which was corrected by increasing
the dose of supplemented folic acid [56]. Nevertheless, car-
riers of MTHFR C677T variant have been shown to be resis-
tant to standard folic acid supplementation requiring higher
doses to achieve less pronounced blood Hcy reductions [57].
Thus, genetic variants may be a resistance factor to the
treatment and a series of issues need to be clarified. Should
we test the patients for MTHFR genotype? What do we do for
homozygous subjects? Can we do better for heterozygous
ones? Are there other genes involved?
Beyond MTHFR variants
MTHFR is not the only enzyme of the 1CC occurring with a
genetic polymorphism of functional consequences, rather the
pathway is a concentrate of potential variants.
The enzyme methionine synthase (MTR) catalyzes the
methylation of Hcy to generate methionine. In case of defec-
tive activity there is lack of Hcy re-cycling. In addition, it is
the only enzyme that uses 5-methyltetrahydrofolate and defi-
cient activity also results in the trapping of cellular folate as 5-
methyltetrahydrofolate [58], which becomes unavailable for
other folate-dependent reactions involved in purine and py-
rimidine biosynthesis. The P1173L mutation, which results in
replacement of proline by leucine at position 1173 of the ami-
no acid sequence, causes megaloblastic anaemia and develop-
mental delay by the age of year 2; however, a series of other
mutations causing only a decreased activity of the enzyme due
to shorter half-life have also been described [59]. Among
these, the A2756G mutation, that is known to cause hyperho-
mocysteinemia, may circulate with high frequency: among an
unselected groups of 125 Turkish children the AG heterozy-
gous state had an incidence of 38% and 5 % of themwere GG
homozygous [60].
The enzyme methionine synthase reductase (MTRR) is re-
sponsible of the reductive activation of MTR. Deficient
MTRR activity causes hyperhomocysteinemia and all symp-
toms of B12 shortage even in presence of normal B12 levels.
The defective MTRR variant A66G has been clinically linked
with high Hcy and occurs with a frequency almost as high as
MTHFR variants: according to a very large survey study in the
USA almost half of the USA population was heterozygous for
MTRRA66Gwith the highest prevalence in the non-Hispanic
white ethnic group [61].
The enzyme betaine homocysteine methyltransferase
(BHMT) is responsible of Hcy methylation using betaine
(trimethylglycine) as the methyl donor. A long list of single
nucleotide polymorphisms (SNPs) has been described, all of
them implicated with the occurrence of reproductive, neoplas-
tic and degenerative diseases, but always within variable as-
sociations with other SNPs of the same gene or of other genes
of metabolic enzymes configuring a kind of genetic puzzle. In
example, the G742A mutation was associated with the occur-
rence of any neural tube defect (NTD) in a USA population
but only in the subgroup of mothers supplemented with folic
acid whereas in non-supplementedmothers it had no influence
[62], suggesting that a BHMT defect may be relevant only in
conditions of folate shortage. In contrast, the same G742A
mutation of BHMT, which occurred respectively in 17 and
7 % of control and case mothers in Canada, was shown to
provide genetic protection against spina bifida [63]. Thus,
very likely the functional effect of this variant, and possibly
of others, depends on the variable associations with other ge-
netic variants and with the feeding habits. Adding further
complexity, the enzyme choline dehydrogenase (CHDH), re-
sponsible to provide the betaine substrate to BHMT and pri-
marily involved in the 1CC, may commonly occur with the
G233T mutation that was proven to cause motility, structure
and energy deficits in sperms of transgenic mice [64]. As a
matter of fact, the absolute prevalence of the BHMT and
CHDH variants and of their association with other enzyme
variants is not known and their phenotypic and functional
outcome remains unpredictable.
As many as 150 clinically relevant mutations of CBS, the
key enzyme for oxy-redox homeostasis, have been described
[65]. In most of the cases, they are non-sense mutations and
also multiple alternatively spliced transcript variants may oc-
cur. The homozygous state for several of these genes is re-
sponsible for homocystinuria, a disease leading to death with-
in the age of 20–30 years. The most common of these muta-
tions, a substitution of threonine for isoleucine at codon 278
(I278T), was found to occur in heterozygous form in 11.7 %
of a control population [66]. It can lead to full homocystinuria
Table 3 Deficit of the MHTFR
function according to the










100 % 66 %% 25 %
1298 AC
Heterozygous 1298C
83 % 48 % Not tested
1298CC
Homozygous 1298C
61 % Not tested Not tested
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or complete compensation according to the homo- or hetero-
zygous state and to the combination with other genetic and
protein splice variants but is usually associated with mild dis-
ease [67] and may account for many subclinical disturbances
of the 1CC and of Hcy homeostasis. Many other single muta-
tions leading to a defective, although non-lethal, function may
occur alone or in association with others so that the genotype-
function relationship of this enzyme remains difficult to
predict.
A schematic map of the possible genetic blockades to the
1CC and the GSH synthesis is depicted in Fig. 4. The picture
does of course include only the primarily involved enzymes,
the list of secondarily involved enzymes and of their variants
is almost unlimited. Further complexity is coming from the
possible epigenetic regulation of the level of expression of
these enzymes, from their mRNA regulation by means of
non-coding RNAs and from the mostly unknown splicing
variants of the encoded proteins.
This complexity explains why a carrier of a heterozygous
MTHFR defective gene may be either well compensated or
seriously metabolically impaired depending on the status of
the other enzymes. Accordingly, the practice to extensively
test the MTHFR genetic status in subfertile men and women
is a kind of non-sense. It is clear that any individual risk
assessment would require testing a variety of SNPs from a
variety of possibly involved genes, and we do not even know
how many genes are potentially involved neither we are sure
of which are the SNPs relevant to functional defects. Even less
is known about the phenotype and function level resulting
from their highly variable associations. In our opinion, it is a
lot simpler to test blood Hcy in both partners of all subfertile
couples deserving the MTHFR gene analysis to those
resulting with frankly elevated Hcy levels, i.e. above
30 μmol/L. Those homozygous for low activity variants will
benefit from the diagnostic information that unmasks a series
of risk factors, e.g. thromboembolic risk and neurodegenera-
tion. For all the others, any wild type or variant heterozygous
state will not mark any difference, at least as long as we will
remain unable to interpret a so complex picture.
Lessons from the gene-environment interaction
MTHFR variants are clearly linked to infertility and reproduc-
tive pathologies as well as to many life-shortening metabolic,
degenerative and neoplastic diseases; thus, they should disap-
pear within a few generations. Conversely, the variants can be
found in a large part of every populations. How is this
possible?
The answer from the geneticists is clear and final: This is
the best possible demonstration of the gene-environment in-
teraction. The prevalence of defective MTHFR variants clear-
ly increases following a North to South gradient, i.e. the
higher the consumption of a Mediterranean type diet, the
higher the frequency of the defective MTHFR enzyme [50].
Besides the permissive action of the diet, the high prevalence
of MTHFR variants also implies possible positive selection
mechanisms [68], i.e. the variants may carry advantages.
Indeed, cancer is known to be in some cases folate-
Fig. 4 Schematic map of the possible genetic blockades to the 1CC and
the GSH synthesis. All of the enzyme variants of concern have a high
prevalence in the population and the chances for multiple defects are
accordingly high. The final phenotype, i.e. the function of the carbon
metabolism and of the antioxidant defenses, will depend on the variable
combination of these genetic substrates with environmental factors
including the diet and intercurrent diseases. MTHFR Methyl-Tetra-
Hydro-Folate-Reductase, MTR Methionine Synthase, MTRR
Methionine Synthase Reductase, BHMT Betaine Homocysteine Methyl
Transferase, CBS Cistathionine Beta Synthase, CHDH Choline
Dehydrogenase
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dependent and to benefit from an efficient 1CC. Both the main
MTHFR variants have been indicated as a possible resistance
factors to colon cancer [69] and to metastases of myeloid
leukaemia [70], just to quote some examples. In addition,
the proliferation of the plasmodium of malaria is far less effi-
cient in presence of a defective MTHFR and this may explain
the high prevalence of these genes in the Mediterranean area
[71]. In conclusion, a subject carrying a MTHFR variant that
is well compensated by the diet and by the pattern of associ-
ated genetic variants of the other metabolic enzymesmay have
a selective advantage compared to what is considered a
Bnormal^ genotype. In example, the prevalence of MTHFR
A1298C, MTR A2756G and of MTRR A66G, all of them
considered defective variants marking a lower methylation
capacity, was significantly higher in 77 elite athletes as com-
pared to their sedentary controls [72]. A possible speculation
is that a lower rate of homocysteine re-methylation to methi-
onine may funnel homocysteine toward transsfulfurations and
GSH production providing better balance to the increased
ROS production due to a high energy balance in intensively
trained subjects.
For historical and cultural reasons, MTHFR is far better
investigated but it is very likely that similar considerations
may come true also for the other enzymes of concern. Thus,
we should refer to all these functional variants of themetabolic
enzymes as population variants, i.e. a genetic diversity creat-
ing strength in the concerned species, including humans.
Apart a few exceptions, e.g. MTHFR C677T homozygosity
and homocystinuria, none of these mutations constitutes a
pathologic trait per se.
The next point is to understand why Mediterranean diet
compensates a lower MTHFR activity. The folates contained
in many natural foods including meats, in all the fortified
foods and in the vast majority of the dietary supplements are
in the form of folic or folinic acid that necessitates MTHFR
activity to be biologically effective. Lettuce, beans, tomatoes,
broccoli and most of the vegetables typical of the
Mediterranean diet contain the soluble and active form of
folates methyl-tetrahydrofolate [73], i.e. the reduced form that
does not require the activation by MTHFR (Fig. 5). Thus, a
high dietary intake of these vegetables feeds the 1CC and the
activation of antioxidant defences irrespectively of MTHFR
activity. Once compensated by the diet the defective MTHFR
becomes an advantage and its prevalence increases.
Conversely, the Mediterranean population should be warned
that the contemporary trend to quit the traditional feeding
habits may cause the loss of these metabolic advantages and
may generate reproductive issues.
On the other side meats are rich in the as well necessary
B12 and zinc. Indeed, in spite of a potentially high intake of
methyl-tetrahydrofolate, vegans develop fast onset high blood
homocysteine. Thus, the more the diet is varied and compre-
hensive of all type of foods, the higher are the chances to
achieve a balanced support of nutrients independently of the
individual genetic inheritance of enzymes alleles and to enjoy
well efficient 1CC and antioxidant defences.
Issues with folic acid supplementation: un-metabolized
folic acid (UMFA)
Healthy feeding habits and lifestyles are the basic requisite for
a good health and for efficient reproductive function, but in
many instances it may be not enough. The modern lifestyle
makes the adherence to a well varied diet difficult and engag-
ing. In addition, the toxic load from the environment is in-
creasing and may peak in subjects with known (e.g. occupa-
tional) or unknown exposures. Needless to say, subjects ho-
mozygous for any defective variants of the enzymes or
Fig. 5 Food folates compared to supplement folates. The folates found in
food consist of a mixture of reduced folates, mainly 5-Methyl-
Tetrahydrofolate as shown in the figure. They also come with a
polyglutamate tail (not shown), further increasing the solubility, whose
length varies according to the type of food. Dietary supplements and
fortified foods usually contain the synthetic form folic acid that is better
stable, cheaper and easier to manufacture. Folic acid requires enzymatic
reduction by the enzymeMTHFR (see red circles) to become soluble and
bioavailable to cell metabolism. Subjects with a deficient MTHFR
activity may not be able to process loads of the synthetic form. It is also
to be noted that the reduction of folic acid from supplements consumes
proportional amounts of NADPH and may be further hampered by any
oxidative stress causing imbalance of NADP toward the oxidised form
NADP+
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carrying an imbalanced pattern of heterozygosis for several of
the enzymes are further exposed to relative dietary shortages.
This is favoring an increasing haphazard use of dietary
supplements aimed to compensate known or supposed de-
fects, which causes several concerns about a possible over
exposure to folic acid. Indeed every manufacturer of dietary
supplements is including some folic acid by default. Thus,
people consuming more than one supplement, which is very
common [74], accumulate folates and can easily go far above
1 milligramme per day. In addition, more and more food for-
tification public programs are in place and many licenses for
branded foods fortified with folates have been released. The
population of Western countries is nowadays overloaded with
folic acid.
Reduced folates, namely 5-methyltetrahydrofolate, are the
soluble/circulating and bioavailable form of this nutrient
(Fig. 5). The occurrence into the circulation of the non-
reduced forms, usually termed UMFA (UnMetabolized Folic
Acid) is the result of lack of activation and may create meta-
bolic imbalances. A recent survey conducted by the National
Center for Health Statistics (NCHS) in the USA found circu-
lating UMFA in nearly 100 % of the tested population, inde-
pendent of their age or ethnic group, and also in non users of
food supplements [75].
UMFAs are completely ineffective in feeding the 1CC and,
once accumulated, they are predicted to be diverted to pyri-
dine synthesis with the potential to overfeed growing cancers.
Although there is no evidence that an excess of UMFAwould
directly cause any cancers, the risk to accelerate growth and
metastases of already existing cancers is real [76]. This is
predicted by mathematical models [77] and already shown
in the clinical setting for colon adenomas [78] and breast can-
cer [79]. Moreover, UMFA may interfere with immune func-
tions and have been shown to cause a decrease in natural killer
activity [80]. As a matter of fact, even if folic acid is inexpen-
sive and easy to manufacture, food fortification programs
have been questioned both in Europe [81] and in the USA
[75].
Subjects carrying any defective MTHFR variant, being un-
able to metabolize/activate folic acid, are highly exposed to
circulating UMFA and to their clinical consequences.
Accordingly, high folic acid intake should be avoided in these
subjects. In reality, we are doing just the opposite: it is com-
mon practice to supplement the carriers of a homozygous
MTHFR variant with huge doses of folic acid to decrease their
blood Hcy [82]. The mega dose of folic acid, usually 5 mg
corresponding to 25-fold the daily requirements, creates a
huge excess of substrate and is able to normalise the Hcy
levels in many subjects. Although this supplement is cheap
and reimbursed by the national health services in several
countries, this overuse in our opinion constitutes a metabolic
nonsense. We are overloading with folic acid exactly those
subjects that cannot metabolise it, i.e. those subjects where
the negative outcomes of the UMFA syndrome are expected
to peak. As long as we are unclear about the medium and long
term consequences of UMFA exposure, this should be
avoided and alternative remedies, i.e. support extended to
the alternative pathways, should be pursued.
Future directions
In spite of the above complexity, better effective interventions
may be easy to implement. Even if a personalised risk assess-
ment is not possible to date, it is already possible to integrate
the diet so that all of the main potential defects get compen-
sated in the best possible way whatever the genetic substrate.
The MHTFR variant has no influence on the performance
of the 1CC if the diet is rich in reduced folates (raw vegeta-
bles), i.e. methyltetrahydrofolate, which is the soluble, active
form and that does not require MTHFR activation [83]. The
defective variants ofMTR andMTRR can be compensated by
consumption of vi tamin B12 in its act ive form,
methylcobalamin (milk, meats, oilly fish), that will support
Hcy re-cycling from methyltetrahydrofolate independently
of those enzymes [84]. The possible BHMT/CHDH activity
deficiency can be compensated by an excess of substrate, i.e.
consuming larger amounts of betaine and choline (cereals).
Finally, CBS activity defects can be mitigated if the diet is
rich in cysteine donors (sulphurated proteins from wheat,
eggs, soy) that can feed GSH de-novo biosynthesis down-
stream to CBS independently of its activation. Such a varied
dietary regimen, besides being of paramount importance for
the carriers of any of the concerned enzymatic defects, would
be just better than any imbalanced regimen also for those with
a wild-type genetic substrate and should be therefore followed
by everybody independently of any genetic testing.
The above wide range support of micronutrients can be
achieved with a better attention to the diet and is also suitable
for the formulation of supplements (see Table 4) [73, 85–90].
Accordingly, a dietary supplement containing the allowed
amounts of the above substances, of course together with
B2, B3, B6 and chelated zinc (Impryl) was formulated in
tablet form and addressed to clinical testing as a support to
female reproduction. As expected, this treatment is already
showing the ability to normalise Hcy levels in carriers of the
TT phenotype of MTHFR, including those that were partially
or fully resistant to huge doses of folic acid. In addition, while
clinical studies are ongoing, the treatment of open label case
series is already providing interesting information, indeed this
is also a tool to check the relevance of oxidative stress and/or
enzyme variants in specific clinical conditions. We are record-
ing a complete and fast regression of all the signs and symp-
toms from PCOS in most of the treated ladies, likely due to a
decrease of the insulin resistance that is triggered by oxidative
stress [91]. This is a strong argument in favor of a major role
of oxidative damage in the disease. The support also favored
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the increase of the Anti-Mullerian Hormone (AMH) levels
and the decrease of circulating FSH in ladies of advanced
reproductive age, which seems to imply some oxidative mech-
anisms affecting the hypothalamus-pituitary axis in the onset
of ovarian failure. Indeed, methylfolate is the only folate form
permeating the blood-brain barrier and also methylcobalamin
passes with far higher efficacy compared to standard B12.
Thus, the latter outcomes may be directly related to the mod-
ulation of brain metabolism leading to the concept that some
reproductive dysfunctions may depend on oxidative stress
within the brain.
Prospective clinical trials are needed to assess the actual
benefits and limits of this approach, meanwhile, due attention
to the diet so as to include as many as possible different food
sources is highly recommended.
Conclusions: Dear Practitioner…
In summary, there is a complex interaction between the envi-
ronment, genes and our feeding habits. The individual out-
come depends on a variety of genetic, epigenetic and behav-
ioral factors. Clinically relevant damage is commonly occur-
ring, mainly dependent on perturbations of the 1CC and has
the deregulation of DNA re-arrangements among the most
deleterious effects. The diet, in case associated to tailored
supplementations, has the potential to adjust most of the im-
balances in most of the subjects.
Full understanding and proper management of all this
aspects may have a fundamental impact on the reproduc-
tive prognosis as well as on global health. Pending
further understanding of all the involved mechanisms,
there are already good indications to be implemented in
clinical practice:
– Oxidative damage is clinically important because it has
the potential to hamper gamete reproductive competence
and to increase the aneuploidy rate;
– Oral antioxidants are powerful tools with strong pharma-
ceutical effects but misuse occurs easily; their chances to
achieve a metabolic balance are negligible;
– The key to achieve an oxy-redox balance is the support to
cellular homeostatic mechanisms: Full availability of
micronutrients necessary to the 1CC favors the synthesis
of GSH and the function of the endogenous antioxidant
cascade resulting in measurable clinical gains;
– High attention should be given to the damage to the chro-
matin structure and to the epigenetic regulation of the
gametes both in the diagnostic phase and in monitoring
the effects of any interventions;
– The individual genetic status has a primary impact on the
susceptibility to the damage, but risk assessment of the
individual remains difficult to define. The screening of
Hcy levels can be of help in selecting patients that benefit
from a detailed genetic investigation;
– Although cheap and easy, folic acid is just a pre-vitamin
and excessive consumption may create health problems.
Food fortification programs should be further re-consid-
ered. The prescription of huge doses to subjects that do
not metabolise it, e.g. MTHFR variant homozygous, is a
questionable idea;
Table 4 Supplement (Impryl)
ingredients and the respective
food sources [73, 85–89]
Supplement ingredients Food sources
Ingredient Daily dose
Betaine 200 mg Cereals (wheat bran/germ/bread), shrimps,
spinach [85]
L-cystine 200 mg Cysteine: Proteins (sulphurated) from wheat,
eggs, soy, meat [86] and whey/casein [87]
Niacin (vit. B3) 16 mg Milk, eggs, rice, fish, lean meats, legumes [88]
Zinc 10 mg Seafood (crustaceans, seashells), red meat (lamb),
spinach [89]
Pyridoxine (vit. B6) 1.4 mg Poultry, fish, organ meats, potatoes, fruit [89]
Riboflavin (vit. B2) 1.4 mg Eggs, organ meats, lean meats, milk, Green
vegetables [89]
Methylfolate (vit. B9) 400 μg Green vegetables (e.g. spinach, lettuce, broccoli,
endive and radicchio) [73], tomatoes [90]
Methylcobalamin (vit. B12) 2.5 μg Any cobalamin: Fish (seashell, oily fish), meat
(beef liver), poultry, eggs, milk, cheese [89].
Actual content in methylcobalamin is not known.
Supplement ingredient amounts are in line with the Nutrient Reference Values of the European Food Safety
Agency, where applicable. It is to be noted that to provide the whole amount of micronutrients contained in the
supplement more than one standard serving of the suggested foods may be needed. However, a single food, e.g.
eggs, may contain several of the concerned micronutrients
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– Only a balanced and very varied diet has the potential to
fulfill the needs in all subjects, once achieved dietary
supplements can be of further help. Whatever stressed
diet, including vegetarian, hyper-proteic and the like,
has the potential to create pathologic imbalances;
– The activated forms of micronutrients are of greater help
and their requirements can be fulfilled with tailored die-
tary regimens. They can also be provided by dietary
supplements;
– Due attention to the metabolic issues and supportive in-
terventions since the first referral have the potential to
reduce the time to pregnancy of infertile couples and to
increase the final cumulative success rate.
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Glossary
1 Carbon Cycle (1CC) Also called transmethylation pathway,
is a main pathway for non-
photosynthetic organisms to add the
carbon unit to molecules, it is essential






Zinc metallo-enzyme that catalyzes the
transfer of a methyl group from betaine
(trimethylglycine) to homocysteine to
form dimethylglycine and methionine.




Oxidoreductases oxidising choline to
betaine aldehyde, which is ultimately
transformed to betaine by aldehyde
dehydrogenase. Feeds the endogenous




Redox-regulated enzyme having vit.
B6 as essential co-factor and allosteri-
cally up-regulated by SAMe. It forms
cystathionine from Hcy and serine
thereby opening the transsulphuration
pathway leading to GSH synthesis.
Glutathione (GSH) It is a tripeptide formed by cysteine,
glycine and glutamate. Thanks to the -
SH group from cysteine it is able to act
as electron donor forming glutathione
disulfide (GSSG). GSH de-novo
biosynthesis occurs within the
transsulfuration pathway.
Homocysteine (Hcy) It is a non-proteogenic aminoacid sim-
ilar to cysteine and formed by de-
methylation of methionine. Within the
1CC it is re-methylated to methionine
by methyl groups donated by folates or
betaine. It is also the substrate of CBS
for the start of the transsulfuratuion
pathway. Hcy accumulation is toxic to
cells.
Methionine synthase (MTR)It is responsible for the remethylation of
homocysteine from folates and uses vit.
B12 as essential co-factor. After a
reductive activation of the enzyme-
bound cobalamin to methylcobalamin
by MTRR, MTR passes the methyl




It is the enzyme responsible for the
activation of MTR. It operates a
reductive methylation of the oxidised
form of the MTR-cobalamin complex
using SAMe as methyl donor and
NADPH as the electron donor.
Methyl-Tetra-Hydro-Folate-
Reductase (MTHFR)
Reductase containing a bound flavin
cofactor (from riboflavine) and using
NAD(P)H as the electron donor.
MTHFR irreversibly reduces 5,10-
methylenetetrahydrofolate to 5-
methyltetrahydrofolate to feed the




Di-nucleotide acting as electron donor
in oxy-redox reactions. Also occurring
in its phosphate form (NADP) to serve
specific enzymes. The equilibrium be-
tween its reduced (NADH/NADPH)
and oxydised (NAD+/NADP+) form




Ubiquitous substrate involved in in
anabolic methyl group transfers and
transsulfurations. It is formed within
the 1CC by activating adenylation of
methionine and, after releasing the
methyl group to acceptors, forms S-
adenosyl-homocysteine and thereafter
Hcy. It occurs in any cells with a mas-




Pathway responsible for the passage of
the -SH group from Hcy to cysteine.
The opposite passage (forward) occurs
only in bacteria. It is a relevant source
of -SH groups for GSH synthesis and
also contributes to the de-toxication of
high Hcy. It upregulates the 1CC.
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